Breaking News

Aduro Biotech Reaches Milestone

Gets $22.4mn in clinical development payments from Janssen

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Aduro Biotech has received $22.4 million in clinical development milestone payments from Janssen Biotech, the company’s license partner for ADU-214, ADU-741 and other products using Aduro’s LADD technology platform for the treatment of specific cancers. Janssen is responsible for all clinical development for the product candidates within the license agreements. “Our relationship with Janssen has been exceptionally productive, with ADU-214 for the treatment of lung cancer and ADU-741 for the t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters